Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

byBenzinga Newsdesk

September 13, 2022

1 minute read

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

Movers
News

What’s Going On With Paramount Global Stock?

By Erica Kollmann

February 15, 11:42 AM

Berkshire Hathaway, led by Warren Buffet, reduced its position in Paramount by roughly 30.4 million shares and now holds 63.32 million shares.

PARA

Tesla, Nio And 3 Stocks To Watch Heading Into Monday

By Lisa Levin

July 3, 4:02 AM

With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:

ImmunoPrecise’s BioStrand Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery

By Benzinga Newsdesk

November 22, 10:06 AM

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has announced that its subsidiary, BioStrand®, has launched an advanced Retrieval Augmented Generation

IPA

Industry Comparison: Evaluating DexCom Against Competitors In Health Care Equipment & Supplies Industry

By Benzinga Insights

November 16, 12:00 PM

In today’s rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to…

DXCM

Guggenheim Downgrades Rubius Therapeutics to Neutral

Related Posts

What’s Going On With Paramount Global Stock?

Tesla, Nio And 3 Stocks To Watch Heading Into Monday

ImmunoPrecise’s BioStrand Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery

Industry Comparison: Evaluating DexCom Against Competitors In Health Care Equipment & Supplies Industry